Rivaroxaban is a widely used oral Factor Xa inhibitor for the treatment and prevention of venous thromboembolism (VTE), including DVT and PE, and for stroke prevention in non-valvular atrial fibrillation. Known for its once-daily dosing and predictable anticoagulant effect, Rivaroxaban minimizes the need for routine monitoring. As a leading NOAC, Rivaroxaban is trusted by physicians worldwide for its safety, efficacy, and broad therapeutic applications.

Explore Royal Pharma as your potential partner for Rivaroxaban API.